OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking ...
AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...
Zacks Investment Research on MSN
EXEL collaborates with MRK for late-stage colorectal cancer study
Exelixis EXEL announced a clinical development collaboration with pharma giant Merck & Co. MRK to evaluate its pipeline candidate, zanzalintinib, in combination with subcutaneous Keytruda Qlex in the ...
Adding immunotherapy to standard treatment for non-muscle invasive bladder cancer (NMIBC) achieved complete response (CR) in ...
Bank of America Global Healthcare Conference 2026 May 12, 2026 2:20 PM EDTCompany ParticipantsLavina Talukdar - Senior VP & Head ...
Merck’s MRK stock has declined 7.3% in the past month despite announcing a solid first-quarter 2026 report on April 30. Merck beat estimates for both earnings and sales. Total r ...
The news adds two concrete pillars to the Keytruda “patent wall”: (1) Phase 3 OptiTROP-Lung05 shows Keytruda + sac-TMT beats ...
Merck (MRK) stock gains as a cancer drug the company develops with Kelun-Biotech bests its Keytruda blockbuster in a ...
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly ...
By Siddhi Mahatole May 21 (Reuters) - Sichuan Kelun-Biotech Biopharmaceutical said on Thursday its experimental treatment ...
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...
Merck reported higher first-quarter sales and raised its full-year earnings guidance as demand for its flagship Keytruda cancer drug continues to grow. Sales rose 5% to $16.29 billion, boosted by 12% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results